175 related articles for article (PubMed ID: 10075083)
1. Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides.
Watson K; Gooderham NJ; Davies DS; Edwards RJ
Biochem Pharmacol; 1999 Apr; 57(7):775-83. PubMed ID: 10075083
[TBL] [Abstract][Full Text] [Related]
2. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size.
Rusnati M; Coltrini D; Oreste P; Zoppetti G; Albini A; Noonan D; d'Adda di Fagagna F; Giacca M; Presta M
J Biol Chem; 1997 Apr; 272(17):11313-20. PubMed ID: 9111037
[TBL] [Abstract][Full Text] [Related]
3. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
[TBL] [Abstract][Full Text] [Related]
4. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
Chen H; He J; Fong S; Wilcox G; Wood C
J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
[TBL] [Abstract][Full Text] [Related]
5. Zn2+ binding to cysteine-rich domain of extracellular human immunodeficiency virus type 1 Tat protein is associated with Tat protein-induced apoptosis.
Misumi S; Takamune N; Ohtsubo Y; Waniguchi K; Shoji S
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):297-304. PubMed ID: 15117453
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
7. HIV Tat protein requirements for transactivation and repression of transcription are separable.
Brown JA; Howcroft TK; Singer DS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jan; 17(1):9-16. PubMed ID: 9436753
[TBL] [Abstract][Full Text] [Related]
8. Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells.
Shaunak S; Gooderham NJ; Edwards RJ; Payvandi N; Javan CM; Baggett N; MacDermot J; Weber JN; Davies DS
Br J Pharmacol; 1994 Sep; 113(1):151-8. PubMed ID: 7812605
[TBL] [Abstract][Full Text] [Related]
9. Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins.
Tao J; Frankel AD
Proc Natl Acad Sci U S A; 1993 Feb; 90(4):1571-5. PubMed ID: 8434019
[TBL] [Abstract][Full Text] [Related]
10. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities.
Litovchick A; Lapidot A; Eisenstein M; Kalinkovich A; Borkow G
Biochemistry; 2001 Dec; 40(51):15612-23. PubMed ID: 11747436
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element.
Mayhood T; Kaushik N; Pandey PK; Kashanchi F; Deng L; Pandey VN
Biochemistry; 2000 Sep; 39(38):11532-9. PubMed ID: 10995220
[TBL] [Abstract][Full Text] [Related]
12. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins.
Bugatti A; Urbinati C; Ravelli C; De Clercq E; Liekens S; Rusnati M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2337-45. PubMed ID: 17452490
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin inhibits Tat-dependent transactivation of HIV type 1 LTR.
Jeyaseelan R; Kurabayashi M; Kedes L
AIDS Res Hum Retroviruses; 1996 May; 12(7):569-76. PubMed ID: 8743082
[TBL] [Abstract][Full Text] [Related]
14. The V1/V2 loop of HIV-1 gp120 is necessary for Tat binding and consequent modulation of virus entry.
Cardaci S; Soster M; Bussolino F; Marchiò S
FEBS Lett; 2013 Sep; 587(18):2943-51. PubMed ID: 23916815
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes.
Zauli G; Gibellini D; Celeghini C; Mischiati C; Bassini A; La Placa M; Capitani S
J Immunol; 1996 Sep; 157(5):2216-24. PubMed ID: 8757349
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Tat directly binds to NFkappaB enhancer sequence: role in viral and cellular gene expression.
Dandekar DH; Ganesh KN; Mitra D
Nucleic Acids Res; 2004; 32(4):1270-8. PubMed ID: 14981150
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein.
Mi MY; Zhang J; He Y
Retrovirology; 2005 Nov; 2():71. PubMed ID: 16293193
[TBL] [Abstract][Full Text] [Related]
18. Purification and functional characterization of wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli.
Orsini MJ; García-Martínez LF; Mavankal G; Gaynor RB; Debouck CM
Protein Expr Purif; 1996 Sep; 8(2):238-46. PubMed ID: 8812870
[TBL] [Abstract][Full Text] [Related]
19. TAR-independent activation of HIV-1 requires the activation domain but not the RNA-binding domain of Tat.
Taylor JP; Kundu M; Khalili K
Virology; 1993 Aug; 195(2):780-5. PubMed ID: 8337844
[TBL] [Abstract][Full Text] [Related]
20. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding.
Smith RE; Talhouk JW; Brown EE; Edgar SE
AIDS Res Hum Retroviruses; 1998 Jul; 14(10):851-68. PubMed ID: 9671214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
